Endpoints News
After tumultuous year, Sarepta plots rebound with early data on RNA therapies
Sarepta Therapeutics reported promise in initial findings from clinical studies of two RNA muscle disease treatments, as the company maps out a future beyond its controversial Duchenne muscular dystrophy therapies.
Sarepta is developing RNA treatments …